Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer
E Potenza, G Parpinel, ME Laudani… - The International …, 2020 - journals.sagepub.com
Introduction: At present there is no predictive value univocally associated with the success of
chemotherapy. Biomarkers produced by ovarian cancer (HE4 and Ca125) could have a …
chemotherapy. Biomarkers produced by ovarian cancer (HE4 and Ca125) could have a …
The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients
KD Steffensen, M Waldstrøm, I Brandslund… - International Journal of …, 2012 - ijgc.bmj.com
Objective A risk-of-ovarian-malignancy algorithm (ROMA) based on human epididymis
protein 4 (HE4) and CA-125 has been reported to categorize women with a pelvic mass into …
protein 4 (HE4) and CA-125 has been reported to categorize women with a pelvic mass into …
Role of HE4, CA72. 4, and CA125 in monitoring ovarian cancer
T Granato, C Midulla, F Longo, B Colaprisca, L Frati… - Tumor Biology, 2012 - Springer
The aim of this study was to investigate the role of biomarkers CA125, HE4, and CA72. 4 at
diagnosis and throughout the follow-up in patients with epithelial ovarian cancer (EOC) …
diagnosis and throughout the follow-up in patients with epithelial ovarian cancer (EOC) …
Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer
J Allard, E Somers, R Theil, RG Moore - Journal of Clinical Oncology, 2008 - ascopubs.org
5535 Background: The serum biomarker CA125 is effectively used for monitoring response
to therapy and monitoring for recurrent disease in patients with epithelial ovarian cancer …
to therapy and monitoring for recurrent disease in patients with epithelial ovarian cancer …
[HTML][HTML] Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer
KD Steffensen, M Waldstrøm… - Oncology …, 2016 - spandidos-publications.com
The majority of ovarian cancer patients with advanced disease at diagnosis will relapse
following primary treatment, with a dismal prognosis. Monitoring the levels of serum markers …
following primary treatment, with a dismal prognosis. Monitoring the levels of serum markers …
[HTML][HTML] Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
Y Rong, L Li - Journal of ovarian research, 2021 - Springer
Objectives To assess the clinical value of early clearance of HE4 and CA125 for platinum
sensitivity and prognosis in patients with ovarian cancer. Method HE4 and CA125 value …
sensitivity and prognosis in patients with ovarian cancer. Method HE4 and CA125 value …
[HTML][HTML] HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial
M Fabbro, PJ Lamy, C Touraine, A Floquet… - Frontiers in …, 2024 - frontiersin.org
HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and
follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for …
follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for …
[HTML][HTML] HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer
A Samborski, MC Miller, A Blackman… - Tumor …, 2022 - content.iospress.com
BACKGROUND: CA125 is the gold standard serum biomarker for monitoring patients with
epithelial ovarian cancer (EOC). Human epididymal protein 4 (HE4) is a novel serum …
epithelial ovarian cancer (EOC). Human epididymal protein 4 (HE4) is a novel serum …
[HTML][HTML] Recent advances in the biomarkers for epithelial ovarian cancer
YH Kim, SC Kim - Journal of gynecologic oncology, 2011 - synapse.koreamed.org
Yun Hwan Kim, et al. http://dx. doi. org/10.3802/jgo. 2011.22. 4.219 220 www. ejgo. org
benign gynecologic disorders contrary to CA-125. The combination of CA-125 with HE4 …
benign gynecologic disorders contrary to CA-125. The combination of CA-125 with HE4 …
Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis
E Gąsiorowska, M Michalak, W Warchoł… - Ginekologia …, 2015 - journals.viamedica.pl
Objectives: The aim of this study was to assess the sensitivity and specificity of HE4 in
detecting and differentiating between types I and II epithelial ovarian cancer (EOC) in …
detecting and differentiating between types I and II epithelial ovarian cancer (EOC) in …